Tony Berberabe, MPH

Articles

Atezolizumab/Cabozantinib Fails to Elicit Benefit Over SOC in Second-line Metastatic NSCLC

April 2nd 2023

Second-line atezolizumab plus cabozantinib did not generate a clinical benefit over standard-of-care docetaxel in patients with metastatic non–small cell lung cancer previously treated with immune checkpoint inhibitors and chemotherapy.

Pembrolizumab Plus Chemotherapy Improves Survival in dMMR/pMMR Advanced Endometrial Cancer

March 28th 2023

Pembrolizumab plus standard-of-care chemotherapy, followed by maintenance pembrolizumab, reduced the risk of disease progression or death vs chemotherapy alone in patients with mismatch repair–deficient and mismatch repair–proficient advanced or recurrent endometrial cancer.

Bevacizumab Plus TAS-102 Increases Survival and DCR in mCRC

January 21st 2023

Third-line bevacizumab plus trifluridine/tipiracil demonstrated a survival and disease control benefit vs trifluridine/tipiracil alone in patients with refractory metastatic colorectal cancer and all clinically relevant subgroups.

Low-Dose Lenalidomide Reduces Risk of Transfusion Dependency, Provides Clonal Response and Safety Benefits in MDS

December 12th 2022

Low doses of lenalidomide prolonged time to and decreased the risk of transfusion dependency and induced quality clonal responses with no increases in progression rate or clonal evolution in patients with low-risk myelodysplastic syndrome.

ARV-471 Monotherapy Demonstrates Clinical Benefit in ER+/HER2- Advanced Breast Cancer

December 8th 2022

ARV-471 monotherapy elicited a significant clinical benefit rate in patients with estrogen receptor–positive/HER2-negative locally advanced or metastatic breast cancer who had undergone prior hormonal therapy and chemotherapy, including those with ESR1 mutations.

REGN5458 Elicits Promising Responses, Safety in Relapsed/Refractory Myeloma

August 27th 2022

REGN5458 produced durable responses with low rates of cytokine release syndrome in patients with relapsed/refractory multiple myeloma.

Pembrolizumab Triplet Prolongs PFS and OS Across Subgroups in Persistent, Recurrent, and Metastatic Cervical Cancer

June 6th 2022

Pembrolizumab plus chemotherapy with or without bevacizumab prolonged progression-free survival and overall survival in key subgroups of patients with persistent, recurrent, or metastatic cervical cancer, displaying benefits similar to those seen in the broader patient population.

Selpercatinib Demonstrates Promising Activity in RET Fusion-Positive Solid Tumors

June 5th 2022

Extended follow-up data from the LIBRETTO-001 demonstrated that selpercatinib elicited durable responses in patients with RET fusion-positive solid tumors, including refractory gastrointestinal malignancies.

Lenvatinib Plus Pembrolizumab Bolsters PFS2 Outcomes in Advanced Endometrial Cancer

June 5th 2022

The combination of lenvatinib and pembrolizumab demonstrated clinically meaningful improvements in progression-free survival on next line of therapy among all-comer patients with advanced endometrial cancer and those with DNA mismatch repair proficient disease, according to an exploratory analysis of the phase 3 KEYNOTE-775 trial.

Epcoritamab Plus R-CHOP Shows Efficacy and Tolerability as First-Line Treatment for High-Risk DLBCL

June 4th 2022

The addition of subcutaneous epcoritamab to standard-of-care R-CHOP demonstrated clinically meaningful response in the first-line treatment of patients with high-risk diffuse large B-cell lymphoma according to updated results of a single-arm of the EPCORE NHL-2 trial.

Infigratinib Generates Activity in FGFR-Mutated Urothelial Carcinoma

May 16th 2022

Infigratinib yielded notable activity and tolerability in patients with localized upper tract urothelial carcinoma harboring FGFR1/2/3 mutations.

Quality of Life Is Maintained With Mitomycin Gel in Low-Grade Non–Muscle Invasive Bladder Cancer

May 16th 2022

Patients with low-grade non-muscle invasive bladder cancer who received the chemoablative reverse thermal gel UGN-102 were found to have maintained health-related quality-of-life outcomes.

Axi-cel Demonstrates Durable Responses in Indolent Non-Hodgkin Lymphoma

April 25th 2022

Axicabtagene ciloleucel continued to elicit high response rates and durable activity in patients with relapsed/refractory follicular lymphoma and marginal zone lymphoma, according to updated findings from the phase 2 ZUMA-5 trial.

Sotigalimab Plus Pembrolizumab Elicits Broad Immune Activity in Metastatic Melanoma

April 13th 2022

The combination of the CD40 agonist antibody sotigalimab and pembrolizumab demonstrated a favorable safety profile and led to immunologic changes that correlated with clinical response in patients with unresectable stage III or IV metastatic melanoma.

Second-Line Cabozantinib Produces Similar Outcomes in RCC, Regardless of Frontline Immunotherapy Choice

February 19th 2022

Treatment with cabozantinib (Cabometyx, Cometriq) in the second-line setting generated similar time-to-event end points and response rates in patients with advanced renal cell carcinoma, regardless of frontline immune-oncology combinations.

Niraparib Plus Cabozantinib Shows Early Promise in Advanced Urothelial and Kidney Cancer

February 18th 2022

Niraparib in combination with cabozantinib demonstrated a manageable safety profile, with preliminary efficacy observed in heavily pretreated patients with metastatic urothelial carcinoma.

Regorafenib Plus Pembrolizumab Misses PFS End Point in Microsatellite Stable CRC

January 22nd 2022

Pembrolizumab plus regorafenib failed to demonstrate a significant improvement in progression-free survival in pretreated patients with microsatellite stable colorectal cancer (MSSCRC), missing the primary end point of the phase 1/2 trial.

Daratumumab Plus RVd Demonstrates Sustained Improvements in Response in Newly Diagnosed Multiple Myeloma

December 15th 2021

The addition of daratumumab to lenalidomide, bortezomib, and dexamethasone continued to elicit improved outcomes vs RVd alone in patients with newly diagnosed, transplant-eligible multiple myeloma, according to findings from the extended 2-year follow-up analysis of the phase 2 GRIFFIN trial.

IPSS, JAK2 Status May Identify Risk for Thrombosis in Primary Myelofibrosis

December 12th 2021

The use of the International Prognostic Scoring System score and JAK2 mutation status may identify patients at risk for major arterial and venous thrombosis in primary myelofibrosis, and suggests appropriate anti-thrombotic prophylaxis.

Pyrotinib Plus Capecitabine Shows Improved OS Over Lapatinib in HER2+ Breast Cancer

December 9th 2021

Pyrotinib plus capecitabine exhibited longer overall survival (OS), compared with lapatinib plus capecitabine, in patients with HER2-positive breast cancer